Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Frazier Healthcare Partners
BioCentury | Dec 20, 2022
Management Tracks
Nolan succeeding Session as CEO of Taysha
Plus: Carmona named CFO at ADC, and updates from NewAmsterdam, CRISPR, Ikena, CN bio and more
BioCentury | Oct 26, 2022
Politics, Policy & Law
Biotech women mobilize ahead of midterms
Call on industry, FDA to step up for women impacted by Dobbs decision
BioCentury | Oct 6, 2022
Finance
Lukatch, Cochran backing West Coast spinouts with Red Tree’s $272M first fund
New VC has invested in 10 companies, most with female co-founders, CEOs
BioCentury | Jul 26, 2022
Regulation
July 25 Quick Takes: SPAC to take NewAmsterdam public
Plus Enhertu under review in HER2-low breast cancer and updates from Rona, Sanofi, Sandoz and more
BioCentury | Jul 1, 2022
Finance
After Forty Seven takeout, MacQuitty finding ‘freedom’ with Lightspeed team
Hybrid firm’s ‘leap’ backing Stanford spinout spurred more life sciences deals, with onetime Abingworth partner building team and portfolio
BioCentury | May 5, 2022
Regulation
May 4 Quick Takes: FDA clears Fujirebio’s Alzheimer’s diagnostic
Plus Jazz licenses sleep disorder therapy from Sumitomo and updates from Apnimed, Phathom, AZ, Kezar
BioCentury | May 3, 2022
Deals
GSK outlasted multiple suitors for Sierra, sweetened bid to $1.9B
SEC filing shows how Sierra’s partnering discussions with GlaxoSmithKline escalated to a 10-figure takeout, with other biopharmas in talks
BioCentury | Apr 30, 2022
Finance
With greenshoe, HilleVax’s NASDAQ IPO could be this year’s biggest to date
After raising $200M, Frazier portfolio company sees shares trade higher in debut
BioCentury | Mar 16, 2022
Finance
Taking ‘patient’ approach, Frazier preparing to write bigger checks from new $987M fund
Continuing previous strategy, Frazier to invest across spectrum from company creation to publicly traded biotechs
BioCentury | Jan 20, 2022
Management Tracks
GSK’s Thirsk joins Bavarian Nordic as COO
Plus Baroldi, Bastings join Ionis, and updates from Exscientia,
Items per page:
1 - 10 of 132